167 related articles for article (PubMed ID: 20055660)
101. Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.
Tam CS; Polliack A
Leuk Lymphoma; 2016; 57(6):1247-8. PubMed ID: 26732524
[No Abstract] [Full Text] [Related]
102. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.
Benson DM; Smith MK
Leuk Lymphoma; 2007 Jul; 48(7):1423-5. PubMed ID: 17613775
[No Abstract] [Full Text] [Related]
103. Inheritance of the cytotoxic factor of human serum.
Bergman S
Nature; 1966 Oct; 212(5061):543. PubMed ID: 5970203
[No Abstract] [Full Text] [Related]
104. Lenalidomide: what is the right dose in CLL?
Lin TS
Blood; 2008 Jun; 111(11):5268. PubMed ID: 18502842
[No Abstract] [Full Text] [Related]
105. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.
Pasiarski M; Rolinski J; Grywalska E; Stelmach-Goldys A; Korona-Glowniak I; Gozdz S; Hus I; Malm A
PLoS One; 2014; 9(12):e114966. PubMed ID: 25506837
[TBL] [Abstract][Full Text] [Related]
106. Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q.
Park I; Phan TM; Fang J
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680233
[TBL] [Abstract][Full Text] [Related]
107. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
108. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.
Rodrigues CA; Gonçalves MV; Ikoma MR; Lorand-Metze I; Pereira AD; Farias DL; Chauffaille ML; Schaffel R; Ribeiro EF; Rocha TS; Buccheri V; Vasconcelos Y; Figueiredo VL; Chiattone CS; Yamamoto M;
Rev Bras Hematol Hemoter; 2016; 38(4):346-357. PubMed ID: 27863764
[TBL] [Abstract][Full Text] [Related]
109. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
110. Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).
Freeman CL; Gribben JG
Curr Hematol Malig Rep; 2016 Feb; 11(1):29-36. PubMed ID: 26857283
[TBL] [Abstract][Full Text] [Related]
111. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
[TBL] [Abstract][Full Text] [Related]
112. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.
Fecteau JF; Corral LG; Ghia EM; Gaidarova S; Futalan D; Bharati IS; Cathers B; Schwaederlé M; Cui B; Lopez-Girona A; Messmer D; Kipps TJ
Blood; 2014 Sep; 124(10):1637-44. PubMed ID: 24990888
[TBL] [Abstract][Full Text] [Related]
113. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
James DF; Werner L; Brown JR; Wierda WG; Barrientos JC; Castro JE; Greaves A; Johnson AJ; Rassenti LZ; Rai KR; Neuberg D; Kipps TJ
J Clin Oncol; 2014 Jul; 32(19):2067-73. PubMed ID: 24868031
[TBL] [Abstract][Full Text] [Related]
114. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Strati P; Keating MJ; O'Brien SM; Ferrajoli A; Burger J; Faderl S; Tambaro FP; Jain N; Wierda WG
Haematologica; 2014 Aug; 99(8):1350-5. PubMed ID: 24859876
[TBL] [Abstract][Full Text] [Related]
115. Trial Watch: Lenalidomide-based immunochemotherapy.
Semeraro M; Vacchelli E; Eggermont A; Galon J; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2013 Nov; 2(11):e26494. PubMed ID: 24482747
[TBL] [Abstract][Full Text] [Related]
116. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
117. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
Strati P; Keating MJ; Wierda WG; Badoux XC; Calin S; Reuben JM; O'Brien S; Kornblau SM; Kantarjian HM; Gao H; Ferrajoli A
Blood; 2013 Aug; 122(5):734-7. PubMed ID: 23801633
[TBL] [Abstract][Full Text] [Related]
118. Treatment options for high-risk chronic lymphocytic leukaemia.
Hewamana S; Dearden C
Ther Adv Hematol; 2011 Jun; 2(3):147-59. PubMed ID: 23556086
[TBL] [Abstract][Full Text] [Related]
119. The emerging role of lenalidomide in the management of lymphoid malignancies.
Hernandez-Ilizaliturri FJ; Batoo SA
Ther Adv Hematol; 2011 Feb; 2(1):45-53. PubMed ID: 23556075
[TBL] [Abstract][Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
